Trials / Completed
CompletedNCT03980509
A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors
A "Window Trial" on Curcumin, the Active Compound in Turmeric, for Invasive Breast Cancer Primary Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.
Detailed description
The purpose of this study is to determine whether oral administration of Curcuma longa extract causes biological changes related to apoptosis (DNA fragmentation) and cell proliferation (Ki67) in primary tumors of breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Curcumin | Curcumin is an extract from turmeric |
Timeline
- Start date
- 2020-01-29
- Primary completion
- 2022-03-24
- Completion
- 2023-03-24
- First posted
- 2019-06-10
- Last updated
- 2025-01-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03980509. Inclusion in this directory is not an endorsement.